<DOC>
	<DOCNO>NCT02840279</DOCNO>
	<brief_summary>This randomize , double-blind ( Investigator subject-blinded ) placebo-controlled , multiple , ascending-dose study evaluate safety , tolerability , pharmacokinetic profile BPN14770 healthy young elderly male female subject provide preliminary assessment cognitive effect BPN14770 healthy elderly subject .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study BPN14770 Healthy Young Elderly Male Female Subjects</brief_title>
	<detailed_description>Objectives : 1 . To evaluate safety tolerability profile multiple oral ascend dose level BPN14770 healthy young elderly subject . 2 . To characterize plasma pharmacokinetic profile BPN14770 follow oral administration healthy young elderly subject . 3 . To provide preliminary assessment cognitive effect BPN14770 healthy elderly subject .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Healthy young male female age 21 45 , inclusive ( Cohorts 1 , 2 , 3 7 ; female subject must pregnant breastfeeding ) , healthy elderly male female ≥ 65 year age ( Cohorts 4 , 5 , 6 ) . 2 . Body mass index 18 kg/m2 32 kg/m2 , inclusive , body weight ≥50 kg ( 110 pound ) . 3 . Female subject must surgically sterile ( bilateral tubal ligation , hysterectomy , bilateral oophorectomy least 6 month prior dose ) , least two year postmenopausal , willing use two barrier method contraception initial screen one month take last dose study drug . Barrier method contraception include diaphragm , cervical cap , male condom , female condom , spermicidal foam sponge . Menopausal status declare female young cohort verify follicle stimulate hormone ( FSH ) test Screening . In addition , female must negative pregnancy test within 48 hour dose Day 1 regardless childbearing potential . 4 . Male subject must willing inform female partner participation study must agree use adequate contraceptive method ( vasectomy perform least 6 month prior dose use least one barrier method birth control ) . 5 . Able understand study procedure , voluntarily consent participate study , provide write informed consent prior start studyspecific procedure . 6 . Willing able remain study unit entire duration confinement period , return outpatient visit . 1 . Clinically significant abnormality , Investigator 's judgement , indicate current hematology , biochemistry , urinalysis test , medical history , social history , vital sign , physical examination . 2 . Positive serology result hepatitis B surface antigen ( HbsAg ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) . 3 . Marked hypotension ( systolic blood pressure [ BP ] ˂90 mmHg diastolic BP ˂50 mmHg ) hypertension ( systolic BP ˃150 mmHg diastolic BP ˃100 mmHg ) base supine sit value obtain Screening , Day1 , Day 1 predose . Outofrange vital sign may repeat eligibility assessment ( prior start dose Day 1 ) . 4 . Marked bradycardia ( heart rate ˂45 beat per minute [ bpm ] ) tachycardia ( heart rate ˃110 bpm ) base supine ECG value obtain Screening , Day 1 , Day 1 predose . Outofrange vital sign may repeat eligibility assessment ( prior start dose Day 1 ) . 5 . Current past history significant ( Investigator 's judgement ) cardiovascular , cerebrovascular , pulmonary , renal , liver disease . Stable , wellcontrolled hypertension hyperlipidemia allow ( see Exclusion # 10 ) . 6 . History hematological disorder ( e.g. , thrombocytopenia ) immediate family ( i.e. , parent sibling ) . 7 . Clinically important significant conduction abnormality single ECG ( include QTc interval ˃450 msec ) evidence history long QT syndrome . This exclusion apply ECGs obtain Screening , Day 1 , Day 1 predose . 8 . Current past history gastric duodenal ulcer diseases gastrointestinal tract could interfere absorption study drug . Note : Subjects history appendectomy cholecystectomy may enrol . 9 . Active acute chronic infectious disease . 10 . Unable discontinue medication include psychotropic drug , sedative antihistamine , centrally active medication [ e.g. , CNS beta blocker ] , moderate strong inhibitor inducer CYP3A4 , CYP2D6 , cytochrome ) . Other prescription nonprescription drug antihypertensive cholesterol lower drug allow , Investigator 's judgement , would interfere test medication cognitive testing . 11 . Any history alcohol drug abuse within previous year prior Screening visit ( per current edition Diagnostic Statistical Manual Mental Disorders , 5th Edition : DSM5 ) , regular ( daily ) consumption alcohol exceed two bottle beer , equivalent amount form alcohol ( 1 serve = 12 oz beer , 5.0 oz wine , 1.5 oz distil spirit ) . 12 . Any use alcohol within 24 hour admission study Day 2 . 13 . Active smoker tobacco user ( e.g. , chew snuff ) unable discontinue tobacco use least 3 month prior admission study Day 2 refrain use tobacco study treatment evaluation period . 14 . Inability unwillingness comply protocol , likely inability complete study . 15 . Participation clinical study involve investigational drug within previous 30 day prior Screening visit . 16 . Donation blood blood product ( include plasma ) 8 week first administration study drug Day 1 . 17 . Positive screen drug abuse cotinine ( screen upon admission ) , positive alcohol result ( upon admission ) . 18 . History allergy penicillin sulfonamide , clinically significant drug allergy include symptom shortness breath , rash , edema . 19 . Inability unwillingness perform task necessary CogState Cognitive Function Assessments ( elderly cohort ) . 20 . A suicidal ideation intensity score 2 high per screen CSSRS assessment and/or suicidal behavior within past 30 day . Cognitive Testing Criteria : Eligibility requirement subject elderly cohort include successful completion computerize battery CogState cognitive function assessment , include : Detection Task ( DET ) Identification Task ( IDN ) One Card Learning Task ( OCL ) One Back Task ( ONB ) Continuous Paired Associate Learning ( CPAL ) International Shopping List Task ( ISLT ) Groton Maze Learning Test ( GMLT )</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>cognition</keyword>
	<keyword>dementia</keyword>
	<keyword>phosphodiesterase type 4D</keyword>
	<keyword>PDE4D</keyword>
</DOC>